Up to 18% of U.S. participants in ENVISION — a Phase 4 post-marketing study of Aduhelm (aducanumab) in early Alzheimer’s disease — will now be enrolled from African American and Latinx populations, the therapy’s developers said in a press release. The aim is to increase diversity in the trial, which seeks to confirm the impact of Aduhelm in early Alzheimer’s. “Historically, patients from diverse backgrounds have been poorly represented in Alzheimer’s disease clinical trials, and we…
You must be logged in to read/download the full post.
The post Aduhelm Phase 4 ENVISION Study to Increase Participant Diversity appeared first on BioNewsFeeds.